Long-term treatment of pulmonary arterial hypertension with macitentan in Japanese patients
暂无分享,去创建一个
Y. Kihara | S. Sasayama | Y. Ozaki | K. Fukuda | T. Minamino | Hiroshi Watanabe | T. Kondo | Y. Okano | N. Tahara | N. Tanabe | K. Yoshioka | H. Dobashi | S. Sakai | S. Joho | S. Ikeda | T. Saji | N. Nakanishi | M. Hatano | M. Funauchi | M. Matsushita | M. Hatta | H. Yamada
[1] Adam Pierozynski,et al. Assessment of Risk of Disease Progression in Pulmonary Arterial Hypertension: Insights from an International Survey of Clinical Practice , 2019, Advances in Therapy.
[2] Z. Jing,et al. Risk stratification and medical therapy of pulmonary arterial hypertension , 2019, European Respiratory Journal.
[3] M. Humbert,et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension , 2017, European Respiratory Journal.
[4] A. Torbicki,et al. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension , 2017, European heart journal.
[5] Y. Kihara,et al. Efficacy and Safety of a Novel Endothelin Receptor Antagonist, Macitentan, in Japanese Patients With Pulmonary Arterial Hypertension. , 2016, Circulation journal : official journal of the Japanese Circulation Society.
[6] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.
[7] M. Iglarz,et al. Comparison of Macitentan and Bosentan on Right Ventricular Remodeling in a Rat Model of Non-vasoreactive Pulmonary Hypertension , 2015, Journal of cardiovascular pharmacology.
[8] Sanjiv J. Shah,et al. Management of Pulmonary Arterial Hypertension , 2015, Seminars in Respiratory and Critical Care Medicine.
[9] M. Humbert,et al. Clinical Pharmacology of Endothelin Receptor Antagonists Used in the Treatment of Pulmonary Arterial Hypertension , 2015, American Journal of Cardiovascular Drugs.
[10] D. Mccrory,et al. Comparative effectiveness and safety of drug therapy for pulmonary arterial hypertension: a systematic review and meta-analysis. , 2014, Chest.
[11] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[12] J. Dingemanse,et al. Pharmacokinetics of Macitentan in Caucasian and Japanese Subjects: The Influence of Ethnicity and Sex , 2013, Pharmacology.
[13] M. Clozel,et al. Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells , 2012, PloS one.
[14] M. Bolli,et al. The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N'-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist. , 2012, Journal of medicinal chemistry.
[15] R. Benza,et al. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. , 2012, Chest.
[16] H. Palevsky,et al. Validation of 6-Minute Walk Distance as a Surrogate End Point in Pulmonary Arterial Hypertension Trials , 2012, Circulation.
[17] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[18] MarcHumbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010 .
[19] M. Humbert,et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension , 2010, European Respiratory Journal.
[20] M. Humbert,et al. Characterization of pulmonary arterial hypertension patients walking more than 450 m in 6 min at diagnosis. , 2010, Chest.
[21] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[22] P. Thomas,et al. Biomarkers in pulmonary hypertension , 2008, European Respiratory Journal.
[23] Richard Sutton,et al. Limitations of the New York Heart Association functional classification system and self-reported walking distances in chronic heart failure , 2006, Heart.
[24] T. Fleming,et al. End points and clinical trial design in pulmonary arterial hypertension. , 2004, Journal of the American College of Cardiology.
[25] A. Shillington,et al. Survival in Primary Pulmonary Hypertension: The Impact of Epoprostenol Therapy , 2002, Circulation.
[26] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[27] Chikayuki Naito,et al. Ethnic Factors in the Acceptability of Foreign Clinical Data , 1998 .
[28] B. Groves,et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. , 1996, The New England journal of medicine.
[29] E H Bergofsky,et al. Survival in Patients with Primary Pulmonary Hypertension: Results from a National Prospective Registry , 1991 .
[30] Simon Gibbs,et al. [2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension]. , 2015, Kardiologia polska.